Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Obesity Therapy
Neurogen announces Phase I clinical trial for proprietary obesity drug
December 11th, 2006
Neurogen Corporation (NRGN) has commenced Phase I human testing of NGD-4715, the company's leading drug candidate for treatment of obesity. The compound works as an antagonist at the melanin concentrating hormone receptor-1 (MCH1). NGD-4715 and other compounds in the company's obesity program are wholly owned by Neurogen. The ongoing Phase I clinical trial is a randomized, double-blind, placebo-controlled evaluation in healthy overweight and obese subjects of the safety, pharmacokinetics, and pharmacodynamics of single rising oral doses of NGD-4715. The study has a planned total enrollment of up to 84 male and female subjects. This single center...
Source: Obesity & Diabetes Week (2006-12-11)
|
